SD-101

Phase 1Small molecule

Merck & Co.

SD-101 is one of 72 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic AdenocarcinomaActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Pancreatic AdenocarcinomaPhase 1

Active, not recruiting

Hepatocellular CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

251 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Preclinical

1 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Doptelet

AAkarx

Preclinical

1 8

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 9

Vermox

WWim Janssens

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Active, not recruiting

Pancreatic Adenocarcinoma

NCT05607953

Phase 1Active, not recruiting

Hepatocellular Carcinoma

NCT06710223

Clinical

Trials by Indication[1]

Lymphoma3 trials

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Terminated·RRobert Lowsky·Phase 1·NCT01745354·6 enrolled

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

Terminated·DDynavax Technologies Corporation·Phase 1/2·NCT02266147·29 enrolled

UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma

Completed·UUniversity of California, Davis·Phase 1/2·NCT03322384·20 enrolled

Tumors1 trial

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated·TTriSalus Life Sciences, Inc.·Phase 1/2·NCT05220722·23 enrolled

Tics1 trial

Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males

Completed·DDynavax Technologies Corporation·Phase 1·NCT00599001·26 enrolled

Chronic Hepatitis1 trial

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Completed·DDynavax Technologies Corporation·Phase 1·NCT00823862·34 enrolled

Uveal Melanoma1 trial

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Terminated·TTriSalus Life Sciences, Inc.·Phase 1·NCT04935229·67 enrolled

6 more indications

Intratumoral Injection1 trial

A Phase I/II Study of Intratumoral Injection of SD-101

Completed·RRobert Lowsky·Phase 1/2·NCT02254772·9 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Terminated·DDynavax Technologies Corporation·Phase 1/2·NCT02521870·241 enrolled

Pancreatic Adenocarcinoma1 trial

Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma

Active, not recruiting·TTriSalus Life Sciences, Inc.·Phase 1·NCT05607953·60 enrolled

Metastatic Prostate Cancer1 trial

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Completed·DDavid Oh·Phase 2·NCT03007732·23 enrolled

Advanced Malignancies1 trial

Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02731742·14 enrolled

Hepatocellular Carcinoma1 trial

A Phase Ib Study of Cryoablation and Pressure-enabled Hepatic Arterial Infusion of Class C Toll-like Receptor 9 Agonist SD-101 in Combination With Durvalumab and Tremelimumab in Patients With Advanced Hepatocellular Carcinoma

Active, not recruiting·UUniversity of California, San Diego·Phase 1·NCT06710223·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for SD-101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SD-101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SD-101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Merck & Co.

SD-101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lymphoma3 trials

Tumors1 trial

Tics1 trial

Chronic Hepatitis1 trial

Uveal Melanoma1 trial

Intratumoral Injection1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Pancreatic Adenocarcinoma1 trial

Metastatic Prostate Cancer1 trial

Advanced Malignancies1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News